Answers are grounded in this paper and cite their sources.
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION: NCT01751568.
No takes yet. Share an insight, caveat, or question.
Krogstad et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: